| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Washington University School of Medicine, Department of Surgery, Biologic Cancer Therapy Program, and Alvin J. Siteman Cancer Center, St. Louis, MO 63110; and
University of California-San Diego School of Medicine, La Jolla, CA 82093
Several systems have been tested for introduction of Ags into human dendritic cells (DC). Most of them to date, however, are complex and possess limited efficiency. Recent advances in HIV trans-activating (TAT) fusion protein technology permit extremely high transduction efficiencies for a majority of mammalian cell types. Here we report our attempts to develop a simple, but highly efficient, protocol for loading of antigenic protein into DC using TAT fusion technology. A TAT-minigene fusion protein was generated, encoding both the HLA-A2-restricted influenza matrix protein-derived epitope (GILVFTFTL, Flu-M1) and a melanoma Ag gp100-derived modified epitope (YLEPGPVTV, G9280-9V). In addition, both a TAT-Her2/neu extracellular domain (ECD) fusion protein and a TAT-green fluorescence protein fusion protein were generated. Over 95% of DC stained positively for TAT-green fluorescence protein within 20 min of coculture. DC treated with TAT-minigene were efficiently recognized by both Flu-M1 and G9280-9V-specific T cells in cytotoxicity assays and IFN-
ELISPOT assays. In contrast, DC pulsed with minigene fusion protein lacking TAT were either poorly recognized or not recognized by the T cells. DC pulsed with TAT-minigene also efficiently induced Flu-M1-specific T cells from naive lymphocytes. Similarly, DC treated with TAT-Her2/neu ECD stimulated patient-derived lymphocytes that specifically recognized Her2/neu+ ovarian and breast cancer cell lines. The CTL induced by TAT-Her2/neu ECD-pulsed DC specifically recognized the Her2/neu ECD-derived immunogenic peptide E75 (KIFGSLAFL). Our data suggest that TAT fusion proteins efficiently transduce DC and induce Ag-specific T cells. This could prove to be a useful method for treatment of infectious diseases and cancer.
This article has been cited by other articles:
|
|
 |
|
  E. Cenci, E. Pericolini, A. Mencacci, S. Conti, W. Magliani, F. Bistoni, L. Polonelli, and A. Vecchiarelli Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide J. Leukoc. Biol., January 1, 2006; 79(1): 40 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Batchu, A. M. Moreno, S. M. Szmania, G. Bennett, G. C. Spagnoli, S. Ponnazhagan, B. Barlogie, G. Tricot, and F. van Rhee Protein Transduction of Dendritic Cells for NY-ESO-1-Based Immunotherapy of Myeloma Cancer Res., November 1, 2005; 65(21): 10041 - 10049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Viehl, M. Becker-Hapak, J. S. Lewis, Y. Tanaka, U. K. Liyanage, D. C. Linehan, T. J. Eberlein, and P. S. Goedegebuure A Tat Fusion Protein-Based Tumor Vaccine for Breast Cancer Ann. Surg. Oncol., July 1, 2005; 12(7): 517 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Flynn, M. Pistello, P. Isola, L. Zaccaro, B. Del Santo, E. Ricci, D. Matteucci, and M. Bendinelli Adoptive Immunotherapy of Feline Immunodeficiency Virus with Autologous Ex Vivo-Stimulated Lymphoid Cells Modulates Virus and T-Cell Subsets in Blood Clin. Vaccine Immunol., June 1, 2005; 12(6): 736 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-D. Wang, W.-Y. F. Sin, G.-B. Xu, H.-H. Yang, T.-y. Wong, X.-W. Pang, X.-Y. He, H.-G. Zhang, J. N. L. Ng, C.-S. S. Cheng, et al. T-Cell Epitopes in Severe Acute Respiratory Syndrome (SARS) Coronavirus Spike Protein Elicit a Specific T-Cell Immune Response in Patients Who Recover from SARS J. Virol., June 1, 2004; 78(11): 5612 - 5618. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
